ONO PHARMA USA continues to expand its organization for enhancement of R&D activities and future commercialization opportunities in the U.S.

CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ — ONO PHARMA USA, INC. (President and CEO, Kunihiko Ito, “OPUS”) announces its organization and leadership team expansion to advance its clinical development, research alliance, licensing activities, as well as future commercialization…

Click here to view original post